Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors
暂无分享,去创建一个
G. Meijer | B. Carvalho | T. van Wezel | F. V. van Leeuwen | P. Snaebjornsson | M. Schaapveld | M. Kerst | M. V. van Leerdam | B. Ykema | E. C. Breekveldt
[1] C. V. van Asperen,et al. Universal immunohistochemistry for Lynch Syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] G. Sauter,et al. Mismatch repair deficiency occurs very rarely in seminomas , 2021, Translational andrology and urology.
[3] F. Balaguer,et al. Comprehensive Genomic Characterization of Fifteen Early-Onset Lynch-Like Syndrome Colorectal Cancers , 2021, Cancers.
[4] A. Viari,et al. Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for “Lynch-like syndrome” including young patients , 2020, European Journal of Human Genetics.
[5] H. Morreau,et al. Prevalence of mismatch repair deficiency and Lynch syndrome in a cohort of unselected small bowel adenocarcinomas , 2020, Journal of Clinical Pathology.
[6] M. Salto‐Tellez,et al. Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series , 2020, Histopathology.
[7] F. Coulet,et al. Molecular tumor testing in patients with Lynch-like syndrome reveals a de novo mosaic variant of a mismatch repair gene transmitted to offspring , 2020, European Journal of Human Genetics.
[8] J. Cubiella,et al. Clinical and Pathological Characterization of Lynch-Like Syndrome. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] A. Gonzalez-Perez,et al. The mutational footprints of cancer therapies , 2019, bioRxiv.
[10] Lik Hang Lee,et al. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade , 2019, Modern Pathology.
[11] N. Ellis,et al. Implication of DNA repair genes in Lynch-like syndrome , 2019, Familial Cancer.
[12] K. Ness,et al. Premature Aging in Young Cancer Survivors. , 2019, Journal of the National Cancer Institute.
[13] Ahmet Zehir,et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Witjes,et al. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Berney,et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] N. Lawrentschuk,et al. Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome , 2018, Bladder cancer.
[17] R. Yantiss,et al. Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing , 2018, Modern Pathology.
[18] L. Adán-Merino,et al. Diagnosis and clinical behavior in patients with Lynch-like syndrome. , 2018, Revista de gastroenterologia de Mexico.
[19] N. LeBrasseur,et al. Biology of premature ageing in survivors of cancer , 2017, ESMO Open.
[20] Russell Bonneville,et al. Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.
[21] L. Rigter,et al. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment , 2016, Gut.
[22] S. Patrick,et al. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. , 2015, DNA repair.
[23] E. Kuipers,et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers , 2014, The Journal of pathology.
[24] D. Dearnaley,et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma , 2013, British Journal of Cancer.
[25] L. Friedova,et al. Second malignancies in long-term testicular cancer survivors , 2014, International Urology and Nephrology.
[26] M. Ladanyi,et al. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency , 2013, Modern Pathology.
[27] J. Potter,et al. Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.
[28] P. Nathan,et al. Secondary Gastrointestinal Cancer in Childhood Cancer Survivors , 2012, Annals of Internal Medicine.
[29] E. Kuipers,et al. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome , 2012, The Journal of pathology.
[30] A. N. Bartley,et al. Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue-Based Mismatch Repair Testing , 2011, Cancer Prevention Research.
[31] P. Okunieff,et al. Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations , 2022 .
[32] K. Hemminki,et al. Second cancers after testicular cancer diagnosed after 1980 in Sweden. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] E. Steyerberg,et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Schellens,et al. Long-term platinum retention after treatment with cisplatin and oxaliplatin , 2008, BMC clinical pharmacology.
[35] M. Louwman,et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Casparie,et al. Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[37] J. Olsen,et al. Second malignancies among survivors of germ‐cell testicular cancer: A pooled analysis between 13 cancer registries , 2007, International journal of cancer.
[38] John D Boice,et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.
[39] X. Lin,et al. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. , 2001, Cancer research.
[40] D. Sleijfer,et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.
[41] P. Hall,et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.
[42] S. Aebi,et al. The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.
[43] A. Stiggelbout,et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] P. Tothill,et al. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. , 1992, European journal of cancer.
[45] E. Reed,et al. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. , 1992, Cancer research.
[46] R. Lothe,et al. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. , 1990, British Journal of Cancer.